Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors.

Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O'Donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, Finn R, Larson S, Scher HI.

Clin Cancer Res. 2007 May 1;13(9):2707-13.

2.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.

J Clin Oncol. 2007 Feb 10;25(5):540-7.

PMID:
17290063
3.

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB.

Cancer Res. 1999 Jul 1;59(13):3192-8.

4.

Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer.

Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, Larson S, Scher HI.

Clin Cancer Res. 2005 Oct 15;11(20):7454-61.

5.
6.

In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.

Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH.

Cancer Res. 2000 Sep 15;60(18):5237-43.

7.

A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.

Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1215-27.

PMID:
15001266
8.

Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate.

Moffatt S, Papasakelariou C, Wiehle S, Cristiano R.

Gene Ther. 2006 May;13(9):761-72.

PMID:
16453011
9.

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH.

J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9. Review.

PMID:
14610416
10.

[Mechanisms of antibody-based therapy against solid tumors].

Nishina S, Yoshida K, Nakagawa K.

Nihon Rinsho. 2012 Dec;70(12):2093-7. Review. Japanese.

PMID:
23259379
11.

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, Nanus DM, Bander NH.

J Nucl Med. 2005 May;46(5):850-8.

12.

Complexity of tumor vasculature and molecular targeting therapies.

Furuya M, Nagahama K, Ishizu A, Otsuka N, Nagashima Y, Aoki I.

Front Biosci (Elite Ed). 2011 Jan 1;3:549-61. Review.

PMID:
21196334
13.

Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?

Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ.

J Nucl Med. 2005 Apr;46(4):634-41.

14.

Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.

Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, Ofner D, Zelger B, Ensinger C, Yang XJ, Geley S, Margreiter R, Bander NH.

Hum Pathol. 2009 Dec;40(12):1754-61. doi: 10.1016/j.humpath.2009.06.003. Epub 2009 Aug 27.

PMID:
19716160
15.

Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies.

Dvorak HF, Nagy JA, Dvorak AM.

Cancer Cells. 1991 Mar;3(3):77-85. Review.

PMID:
1711364
16.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

17.

Recombinant antibodies for the selective targeting of tumor neovasculature.

Viti F, Giovannoni L, Neri D.

Curr Opin Drug Discov Devel. 2002 Mar;5(2):204-13. Review.

PMID:
11926127
18.

Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody.

Carter T, Sterling-Levis K, Ow K, Doughty L, Hattarki M, Shapira D, Hewish D, Kortt AA, Russell PJ.

Cancer Immunol Immunother. 2004 Jun;53(6):533-42. Epub 2004 Jan 13.

PMID:
14722669
19.
20.

Antibody-based vascular tumor targeting.

Schliemann C, Neri D.

Recent Results Cancer Res. 2010;180:201-16. doi: 10.1007/978-3-540-78281-0_12. Review.

PMID:
20033385

Supplemental Content

Support Center